Cargando…
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis and atherogenesis. However, there are only limited rodent models, with a functional low-density lipoprotein receptor (LDLR) pathway and cholesteryl ester transfer protein (CETP) to evaluate the drug can...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929182/ https://www.ncbi.nlm.nih.gov/pubmed/31779098 http://dx.doi.org/10.3390/ijms20235936 |
_version_ | 1783482646012100608 |
---|---|
author | Wu, Yue Xu, Ming-Jiang Cao, Zhiyou Yang, Chun Wang, Jinjie Wang, Bijue Liu, Jian Wang, Yuhui Xian, Xunde Zhang, Fang Liu, George Chen, Xiaoli |
author_facet | Wu, Yue Xu, Ming-Jiang Cao, Zhiyou Yang, Chun Wang, Jinjie Wang, Bijue Liu, Jian Wang, Yuhui Xian, Xunde Zhang, Fang Liu, George Chen, Xiaoli |
author_sort | Wu, Yue |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis and atherogenesis. However, there are only limited rodent models, with a functional low-density lipoprotein receptor (LDLR) pathway and cholesteryl ester transfer protein (CETP) to evaluate the drug candidates targeting the PCSK9/LDLR pathway, that are translatable to humans. Here, by using our recently generated LDLR heterozygote (Ldlr+/−) hamster model with functional LDLR pathway and CETP function, we seek to evaluate the effect of a PCSK9 antibody, evolocumab, on dyslipidemia and atherosclerosis compared with ezetimibe, an effective inhibitor of cholesterol absorption, as a positive therapeutic control. We show that the plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) were significantly increased in Ldlr+/− hamsters fed a high-fat high-cholesterol (HFHC) diet; therefore, areas of atherosclerotic lesion in the aorta were obviously increased and positively correlated with plasma LDL-C and TC. Circulating free PCSK9 was downregulated by the HFHC diet and was undetectable in the evolocumab treated group, as expected. Most importantly, either evolocumab or ezetimibe treatment prevented HFHC diet-induced hyperlipidemia and subsequent atherosclerotic plaque formation. The results indicate that Ldlr+/− hamsters fed an HFHC diet represent an ideal rodent model to evaluate drug candidates that affect LDLR pathways. |
format | Online Article Text |
id | pubmed-6929182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69291822019-12-26 Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis Wu, Yue Xu, Ming-Jiang Cao, Zhiyou Yang, Chun Wang, Jinjie Wang, Bijue Liu, Jian Wang, Yuhui Xian, Xunde Zhang, Fang Liu, George Chen, Xiaoli Int J Mol Sci Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis and atherogenesis. However, there are only limited rodent models, with a functional low-density lipoprotein receptor (LDLR) pathway and cholesteryl ester transfer protein (CETP) to evaluate the drug candidates targeting the PCSK9/LDLR pathway, that are translatable to humans. Here, by using our recently generated LDLR heterozygote (Ldlr+/−) hamster model with functional LDLR pathway and CETP function, we seek to evaluate the effect of a PCSK9 antibody, evolocumab, on dyslipidemia and atherosclerosis compared with ezetimibe, an effective inhibitor of cholesterol absorption, as a positive therapeutic control. We show that the plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) were significantly increased in Ldlr+/− hamsters fed a high-fat high-cholesterol (HFHC) diet; therefore, areas of atherosclerotic lesion in the aorta were obviously increased and positively correlated with plasma LDL-C and TC. Circulating free PCSK9 was downregulated by the HFHC diet and was undetectable in the evolocumab treated group, as expected. Most importantly, either evolocumab or ezetimibe treatment prevented HFHC diet-induced hyperlipidemia and subsequent atherosclerotic plaque formation. The results indicate that Ldlr+/− hamsters fed an HFHC diet represent an ideal rodent model to evaluate drug candidates that affect LDLR pathways. MDPI 2019-11-26 /pmc/articles/PMC6929182/ /pubmed/31779098 http://dx.doi.org/10.3390/ijms20235936 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Yue Xu, Ming-Jiang Cao, Zhiyou Yang, Chun Wang, Jinjie Wang, Bijue Liu, Jian Wang, Yuhui Xian, Xunde Zhang, Fang Liu, George Chen, Xiaoli Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title | Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title_full | Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title_fullStr | Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title_full_unstemmed | Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title_short | Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis |
title_sort | heterozygous ldlr-deficient hamster as a model to evaluate the efficacy of pcsk9 antibody in hyperlipidemia and atherosclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929182/ https://www.ncbi.nlm.nih.gov/pubmed/31779098 http://dx.doi.org/10.3390/ijms20235936 |
work_keys_str_mv | AT wuyue heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT xumingjiang heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT caozhiyou heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT yangchun heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT wangjinjie heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT wangbijue heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT liujian heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT wangyuhui heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT xianxunde heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT zhangfang heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT liugeorge heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis AT chenxiaoli heterozygousldlrdeficienthamsterasamodeltoevaluatetheefficacyofpcsk9antibodyinhyperlipidemiaandatherosclerosis |